Pharmacotherapy for irritable bowel syndrome in the context of evidence-based medicine


Cite item

Full Text

Abstract

The paper analyzes an evidence base for the pharmacotherapy of irritable bowel syndrome (IBS) A large number of randomized placebo-controlled trials (RPCTs) systematized in a number of meta-analyses suggest that monotherapy regimens with spasmolytics, antidepressants, dietary fibers, polyethylene glycol, rifaximin, probiotics, and mesalamine are effective. Only some RPCTs evaluate the efficiency of combined pharmacotherapy versus placebo for IBS. Since the basis for the pathophysiology of the latter is motility and functional disorders, visceral hypersensitivity, and, probably, impaired microbiota, we anticipate that the need to use combined approaches to treating the majority of patients with IBS, by covering a few components of its pathogenesis, is relevant. Thus, to choose pharmacotherapy for IBS in each specific case is a challenge as this is determined by the form of IBS, the availability of an approved medicine on the domestic market, the indications for use, possible long-term use, high safety, and efficacy evidence drawn from RPCTs.

References

  1. Drossman D.A. The Functional Gastrointestinal Disorders and the Rome III Process. Gastroenterology 2006; 130 (5): 1377-1390.
  2. Talley N.J., Gabriel S.E., Harmsen W.S. et al. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology. 1995; 109 (6): 1736-1741.
  3. Canavan C., West J., Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014; 6: 71-80.
  4. Andrae D.A., Patrick D.L., Drossman D.A., Covington P.S. Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients. Health Qual Life Outcomes 2013; 11: 208.
  5. Hahn B.A., Yan S., Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion 1999; 60: 77-81.
  6. Mayer E.M., Hays R.D., Kilbourne A. et al. Impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 1999; 116: A1038.
  7. Naliboff B.D., Kim S.E., Bolus R. et al. Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis. Am J Gastroenterol 2012; 107 (3): 451-459.
  8. Маев И.В., Черемушкин С.В., Самсонов А.А. и др. Синдром раздраженного кишечника (Алгоритм диагностики и лечебной тактики). Учебное пособие. М 2006.
  9. Маев И.В., Кучерявый Ю.А., Черемушкин С.В. Эволюция представлений о синдроме раздраженного кишечника. Методическое пособие для врачей. М 2013.
  10. Черемушкин С.В., Кучерявый Ю.А., Черемушкина Н.В., Кривобородова Н.А. Возможности купирования боли при синдроме раздраженного кишечника. Фарматека 2013; 18: 84-93.
  11. Spiller R., Lam C. An Update on post-infectious irritable bowel syndrome: Role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil 2012; 18 (3): 258-268.
  12. Levy R.L., Jones K.R., Whitehead W.E. et al. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001; 121: 799-804.
  13. van der Veek P.P., van den Berg M., de Kroon Y.E. et al. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005; 100: 2510-2516.
  14. Barbara G., Stanghellini V., De Giorgio R. et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702.
  15. Черемушкин С., Маев И., Кучерявый Ю., Черемушкина Н. Спазмолитики при синдроме раздраженного кишечника с позиций доказательной медицины. Врач 2012; 1: 45-52.
  16. Hayes P.A., Fraher M.H., Quigley E.M. Irritable bowel syndrome: the role of food in pathogenesis and management. Gastroenterol Hepatol (NY) 2014; 10 (3): 164-174.
  17. Chey W.D., Olden K., Carter E. et al. Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U.S. women. Am J Gastroenterol 2002; 97: 2803-2811.
  18. Monsbakken K.W., Vandvik P.O., Farup P.G. Perceived food intolerance in subjects with irritable bowel syndrome-etiology, prevalence, and consequences. Eur J Clin Nutr 2006; 60: 667-672.
  19. Halmos E.P., Power V.A., Shepherd S.J. et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014; 146 (1): 67-75.
  20. Eswaran S., Goel A., Chey W.D. What role does wheat play in the symptoms of irritable bowel syndrome? Gastroenterol Hepatol NY. 2013; 9 (2): 85-91.
  21. Vazquez-Roque M., Camilleri M., Smyrk T. et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology 2013; 144 (5): 903-911.
  22. Маев И.В., Черемушкин С.В., Кучерявый Ю.А., Черемушкина Н.В. Спазмолитическая терапия синдрома раздраженного кишечника, основанная на принципе доказательной медицины. Фарматека 2012; 10 (243): 16-22.***
  23. Martínez-Vázquez M.A., Vázquez-Elizondo G., González-González J.A. et al. Effect of antispasmodic agents, alone or in combination, in the treatment of irritable bowel syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex 2012; 77 (2): 82-90.
  24. Poynard T., Regimbeau C., Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15 (3): 355-361.
  25. Ford A.C., Talley N.J., Spiegel B.M. et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313.
  26. Brandt L., Chey W., Foxx-Orenstein A. et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 (1): 1-35.
  27. Ruepert T., Quartero А., de Wit N. et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritаblе bowel syndrome. Тhе Cochrane Library 2011; 8.
  28. World Gastroenterology Organization. Global Guideline. Irritable bowel syndrome: a global perspective 2009.
  29. Korterink J.J., Ockeloen L., Benninga M.A. et al. Probiotics for childhood functional gastrointestinal disorders: a systematic review and meta-analysis. Acta Paediatr 2014; 103 (4): 365-372.
  30. Ortiz-Lucas M., Tobías A., Saz P., Sebastián J.J. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. Rev Esp Enferm Dig 2013; 105 (1): 19-36.
  31. Ford A.C., Talley N.J., Quigley E.M., Moayyedi P. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 2009; 52 (10): 1805-1806.
  32. Кучерявый Ю.А., Черемушкин С.В., Маевская Е.А., Сутугина Е.А. Взаимосвязь синдромов раздраженного кишечника и избыточного бактериального роста: есть ли она? Рос журн гастроэнтерол, гепатол, колопроктол 2014; 2: 5-14.
  33. Pimentel M., Lembo A., Chey W.D. et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32.
  34. Schoenfeld P., Pimentel M., Chang L. et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2014; 39 (10): 1161-1168.
  35. Salix receives anticipated FDA complete response letter on XIFAXAN 500 mg tablets Non-C IBS Supplemental New Drug Application. Salix Pharmaceuticals, Inc 2011.
  36. Corinaldesi R., Stanghellini V., Cremon C. et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 2009; 30 (3): 245-252.
  37. Dorofeyev A.E., Kiriyan E.A., Vasilenko I.V. et al. Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome. Clin Exp Gastroenterol 2011; 4: 141-153.
  38. Полевая Е.В., Вахитов Т.Я., Ситкин С.И. Энтеросорбционные свойства псиллиума (Мукофалька) и возможные механизмы его действия при кишечных инфекциях. Клин перспект гастроэнтерол, гепатол 2012; 2: 35-39.
  39. Черемушкин С., Кучерявый Ю., Гончаренко А. и др. Ретроспективная оценка эффекта последействия полиэтиленгликоля при лечении хронического запора. Врач 2013; 3: 58-62.
  40. Chapman R.W., Stanghellini V., Geraint M., Halphen M. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol 2013; 108 (9): 1508-1515.
  41. Everitt H.A., Moss-Morris R.E., Sibelli A. et al. Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website (MIBS trial). BMC Gastroentero. 2010; 10: 136.
  42. Abbas Z., Yakoob J., Jafri W. et al. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. Eur J Gastroenterol Hepatol 2014; 26 (6): 630-639.
  43. Grundmann O., Yoon S.L. Complementary and alternative medicines in irritable bowel syndrome: an integrative view. World J Gastroenterol 2014; 20 (2): 346-362.
  44. Peckham E.J., Nelson E.A., Greenhalgh J. et al. Homeopathy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2013; 11: CD009710.
  45. Manheimer E., Cheng K., Wieland L.S. et al. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2012; 5: CD005111.
  46. Catanzaro R., Occhipinti S., Calabrese F. et al. Irritable bowel syndrome: new findings in pathophysiological and therapeutic field. Minerva Gastroenterol Dieto. 2014; 60 (2): 151-163.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies